DC-PrecisionCancerTherapy

Antibody-Drug Conjugates

Precision Cancer Therapy Driving Investment and Innovation Antibody-drug conjugates (ADCs) are rapidly emerging as a transformative force in precision medicine, revolutionizing cancer treatment by combining the targeting precision of monoclonal…
READ MORE

Competition in the Biotech Industry

The biotech industry is characterized by intense competition stemming from scientific breakthroughs, innovative therapies, and cutting-edge technologies. Biotech CEOs encounter…
READ MORE

Navigating the Complexities of Market Access and Reimbursement in the US Biotech Industry

In the intricate landscape of biotechnology, the path to introducing innovative products comes with challenges that require strategic expertise. Overcoming…
READ MORE

Navigating Biotech Product Licensing in China: Bridging Opportunity and Complexity

Embarking on the global biotech stage, the allure of the Chinese market beckons with undeniable potential. Yet, the path to…
READ MORE

Navigating the Complex Intellectual Property Landscape as a Biotech CEO

As a Biotech CEO, steering a company through the dynamic landscape of innovation comes with a unique set of challenges,…
READ MORE

Exploring Funding Avenues for your Biotech Venture

In the dynamic landscape of biotech, securing the right funding is the heartbeat of progress. For innovative startups in this…
READ MORE

Licensing Strategies for Biotech CEOs

Biotech research and development serve as the bedrock of groundbreaking advancements, but the journey often demands substantial financial backing. CEOs…
READ MORE

KYBORA is pleased to announce that Wang Zhi has joined its team at EVP and Managing Director of its Asia Pac operations.

SHANGHAI AND PRINCETON, N.J. JUNE 09, 2023KYBORA Life Sciences, a global advisory firm dedicated to facilitating enduring success for life…
READ MORE

Q1 2023 Global Biopharma Market Trends and News

In this report (download here) , Q1 2023 Global Biopharma Market Trends and News, we cover the key Biotech/Pharma trends…
READ MORE

KYBORA is happy to announce that Khai Meng Ang has joined its team as Senior Advisor for China.

KYBORA's mission is to help life science companies achieve enduring success. Khai's addition to our team allows us to provide…
READ MORE

KYBORA announces that Megalabs has acquired acquired Fr!ska

KYBORA is pleased to announce that its client Megalabs has acquired acquired Fr!ska.
READ MORE
Daewoong License to CS Pharma

KYBORA is pleased to announce the licensing of Daewoong’s development stage IPF therapy (Bersiporocin) to CS Pharmaceuticals for the Greater China region.

KYBORA is pleased to announce the licensing of Daewoong's development stage IPF therapy (Bersiporocin) to CS Pharmaceuticals for the Greater China…
READ MORE

KYBORA is pleased to announce that its trademarks have been approved and registered by the Chinese government.

KYBORA and its Chinese translation (pronounced KAI-BO-RUI) have both been granted official trademark status by the People's Republic of China.
READ MORE

TYPE & ENTER: